Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis
Updated meta-analysis published in Coronary Artery Disease (2023)
Abstract
BACKGROUND: The use of bivalirudin-based anticoagulation over heparin-based anticoagulation for coronary percutaneous intervention has been debated for a long time. Multiple trials have shown promising benefits of bivalirudin over heparin therapy with the most recent addition being the BRIGHT-4 trial. We performed a meta-analysis to assess evidence from these trials, focusing on the coronary intervention of the STEMI population. METHODS: This meta-analysis was performed based on PRISMA guidelines after registering in PROSPERO (CRD42023394701). Databases were searched for relevant articles published before January 2023. Pertinent data from the included studies were extracted and analyzed using RevMan v5.4. RESULTS: Out of 2375 studies evaluated, 13 randomized control trials with 24 360 acute ST-elevation myocardial infarction patients were included for analysis. The bivalirudin-based anticoagulation reduced the net clinical events (OR 0.75, CI 0.61-0.92), major adverse cardiac or cerebral events (OR 0.85, CI 0.74-0.98), any bleeding (OR 0.61, CI 0.45-0.83), major bleeding (OR 0.54, CI 0.39-0.75), all-cause mortality (OR 0.79, CI 0.67-0.92) and cardiac mortality (OR 0.78, CI 0.65-0.93) significantly without increasing the risk of any stent thrombosis (OR 0.92, 95% CI 0.52-1.61), definite stent thrombosis (OR 1.17, 95% CI 0.62-2.22) and acute stent thrombosis (OR 2.06, 95% CI 0.69-6.09) significantly at 30 days. CONCLUSION: Based on this meta-analysis, bivalirudin plus a post-PCI high-dose infusion-based anticoagulation during STEMI PCI has significant benefits over heparin therapy for cardiovascular outcomes without a significant increase in the risk of thrombotic outcomes.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Updated post-BRIGHT-4 STEMI meta-analysis confirming bivalirudin reduces 30-day all-cause mortality and major bleeding in primary PCI versus heparin.
Why This Matters for Hirudotherapy
This meta-analysis of 13 randomized controlled trials (24,360 STEMI patients) assessed bivalirudin-based versus heparin-based anticoagulation during percutaneous coronary intervention, incorporating the BRIGHT-4 trial data. Bivalirudin with post-PCI high-dose infusion significantly reduced net clinical events, major adverse cardiac or cerebral events, all bleeding, major bleeding, all-cause mortality, and cardiac mortality, without significantly increasing stent thrombosis risk. The abstract does not mention leeches, hirudin derivation, or any connection to hirudotherapy, so no defensible link to ASH's domain exists based solely on this article. The findings concern a pharmaceutical anticoagulant in interventional cardiology and cannot be directly related to traditional leech therapy.
Citation
Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis.
Oli PR et al. · Coronary artery disease, 2023
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026